United States Plasma Protease C1-inhibitor Treatment Market Report 2017

November 2017 | 101 pages | ID: UB40F2F1AC9WEN
QYResearch

Abstracts

In this report, the United States Plasma Protease C1-inhibitor Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Plasma Protease C1-inhibitor Treatment in these regions, from 2012 to 2022 (forecast).

United States Plasma Protease C1-inhibitor Treatment market competition by top manufacturers/players, with Plasma Protease C1-inhibitor Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Shire plc
• CSL Limited
• Sanquin
• Pharming Group N.V.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• by Drug Class
• C1-inhibitors
• Kallikrein Inhibitor (Kalbitor)
• Selective Bradykinin B2 Receptor Antagonist (Firazyr)
• by Dosage Type
• Liquid/Injectable
• Lyophilized

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital Pharmacies
• Independent Pharmacies and Outlets

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Plasma Protease C1-inhibitor Treatment Market Report 2017

1 PLASMA PROTEASE C1-INHIBITOR TREATMENT OVERVIEW

1.1 Product Overview and Scope of Plasma Protease C1-inhibitor Treatment
1.2 Classification of Plasma Protease C1-inhibitor Treatment by Product Category
  1.2.1 United States Plasma Protease C1-inhibitor Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Plasma Protease C1-inhibitor Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 C1-inhibitors
  1.2.4 Kallikrein Inhibitor (Kalbitor)
  1.2.5 Selective Bradykinin B2 Receptor Antagonist (Firazyr)
1.3 United States Plasma Protease C1-inhibitor Treatment Market by Application/End Users
  1.3.1 United States Plasma Protease C1-inhibitor Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital Pharmacies
  1.3.3 Independent Pharmacies and Outlets
1.4 United States Plasma Protease C1-inhibitor Treatment Market by Region
  1.4.1 United States Plasma Protease C1-inhibitor Treatment Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
  1.4.3 Southwest Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
  1.4.5 New England Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
  1.4.6 The South Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
  1.4.7 The Midwest Plasma Protease C1-inhibitor Treatment Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Plasma Protease C1-inhibitor Treatment (2012-2022)
  1.5.1 United States Plasma Protease C1-inhibitor Treatment Sales and Growth Rate (2012-2022)
  1.5.2 United States Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2012-2022)

2 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Plasma Protease C1-inhibitor Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Plasma Protease C1-inhibitor Treatment Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Plasma Protease C1-inhibitor Treatment Average Price by Players/Suppliers (2012-2017)
2.4 United States Plasma Protease C1-inhibitor Treatment Market Competitive Situation and Trends
  2.4.1 United States Plasma Protease C1-inhibitor Treatment Market Concentration Rate
  2.4.2 United States Plasma Protease C1-inhibitor Treatment Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Plasma Protease C1-inhibitor Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Plasma Protease C1-inhibitor Treatment Sales and Market Share by Region (2012-2017)
3.2 United States Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Region (2012-2017)
3.3 United States Plasma Protease C1-inhibitor Treatment Price by Region (2012-2017)

4 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Plasma Protease C1-inhibitor Treatment Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Type (2012-2017)
4.3 United States Plasma Protease C1-inhibitor Treatment Price by Type (2012-2017)
4.4 United States Plasma Protease C1-inhibitor Treatment Sales Growth Rate by Type (2012-2017)

5 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Plasma Protease C1-inhibitor Treatment Sales and Market Share by Application (2012-2017)
5.2 United States Plasma Protease C1-inhibitor Treatment Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Shire plc
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Plasma Protease C1-inhibitor Treatment Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Shire plc Plasma Protease C1-inhibitor Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 CSL Limited
  6.2.2 Plasma Protease C1-inhibitor Treatment Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 CSL Limited Plasma Protease C1-inhibitor Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Sanquin
  6.3.2 Plasma Protease C1-inhibitor Treatment Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Pharming Group N.V.
  6.4.2 Plasma Protease C1-inhibitor Treatment Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview

7 PLASMA PROTEASE C1-INHIBITOR TREATMENT MANUFACTURING COST ANALYSIS

7.1 Plasma Protease C1-inhibitor Treatment Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Plasma Protease C1-inhibitor Treatment

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Plasma Protease C1-inhibitor Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Plasma Protease C1-inhibitor Treatment Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Plasma Protease C1-inhibitor Treatment Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Plasma Protease C1-inhibitor Treatment Sales Volume Forecast by Type (2017-2022)
11.3 United States Plasma Protease C1-inhibitor Treatment Sales Volume Forecast by Application (2017-2022)
11.4 United States Plasma Protease C1-inhibitor Treatment Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Plasma Protease C1-inhibitor Treatment
Figure United States Plasma Protease C1-inhibitor Treatment Market Size (K Units) by Type (2012-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume Market Share by Type (Product Category) in 2016
Figure C1-inhibitors Product Picture
Figure Kallikrein Inhibitor (Kalbitor) Product Picture
Figure Selective Bradykinin B2 Receptor Antagonist (Firazyr) Product Picture
Figure United States Plasma Protease C1-inhibitor Treatment Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Plasma Protease C1-inhibitor Treatment by Application in 2016
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Independent Pharmacies and Outlets Examples
Table Key Downstream Customer in Independent Pharmacies and Outlets
Figure United States Plasma Protease C1-inhibitor Treatment Market Size (Million USD) by Region (2012-2022)
Figure The West Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales (K Units) and Growth Rate (2012-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Plasma Protease C1-inhibitor Treatment Sales Share by Players/Suppliers
Figure 2017 United States Plasma Protease C1-inhibitor Treatment Sales Share by Players/Suppliers
Figure United States Plasma Protease C1-inhibitor Treatment Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Plasma Protease C1-inhibitor Treatment Revenue Share by Players/Suppliers
Figure 2017 United States Plasma Protease C1-inhibitor Treatment Revenue Share by Players/Suppliers
Table United States Market Plasma Protease C1-inhibitor Treatment Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Plasma Protease C1-inhibitor Treatment Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Plasma Protease C1-inhibitor Treatment Market Share of Top 3 Players/Suppliers
Figure United States Plasma Protease C1-inhibitor Treatment Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Plasma Protease C1-inhibitor Treatment Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Plasma Protease C1-inhibitor Treatment Product Category
Table United States Plasma Protease C1-inhibitor Treatment Sales (K Units) by Region (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales Share by Region (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Share by Region (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Market Share by Region in 2016
Table United States Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Revenue Share by Region (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Revenue Market Share by Region (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Revenue Market Share by Region in 2016
Table United States Plasma Protease C1-inhibitor Treatment Price (USD/Unit) by Region (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales (K Units) by Type (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales Share by Type (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Share by Type (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Market Share by Type in 2016
Table United States Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Plasma Protease C1-inhibitor Treatment by Type (2012-2017)
Figure Revenue Market Share of Plasma Protease C1-inhibitor Treatment by Type in 2016
Table United States Plasma Protease C1-inhibitor Treatment Price (USD/Unit) by Types (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Growth Rate by Type (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales (K Units) by Application (2012-2017)
Table United States Plasma Protease C1-inhibitor Treatment Sales Market Share by Application (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Market Share by Application (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Market Share by Application in 2016
Table United States Plasma Protease C1-inhibitor Treatment Sales Growth Rate by Application (2012-2017)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Growth Rate by Application (2012-2017)
Table Shire plc Basic Information List
Table Shire plc Plasma Protease C1-inhibitor Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Shire plc Plasma Protease C1-inhibitor Treatment Sales Growth Rate (2012-2017)
Figure Shire plc Plasma Protease C1-inhibitor Treatment Sales Market Share in United States (2012-2017)
Figure Shire plc Plasma Protease C1-inhibitor Treatment Revenue Market Share in United States (2012-2017)
Table CSL Limited Basic Information List
Table CSL Limited Plasma Protease C1-inhibitor Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure CSL Limited Plasma Protease C1-inhibitor Treatment Sales Growth Rate (2012-2017)
Figure CSL Limited Plasma Protease C1-inhibitor Treatment Sales Market Share in United States (2012-2017)
Figure CSL Limited Plasma Protease C1-inhibitor Treatment Revenue Market Share in United States (2012-2017)
Table Sanquin Basic Information List
Table Sanquin Plasma Protease C1-inhibitor Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanquin Plasma Protease C1-inhibitor Treatment Sales Growth Rate (2012-2017)
Figure Sanquin Plasma Protease C1-inhibitor Treatment Sales Market Share in United States (2012-2017)
Figure Sanquin Plasma Protease C1-inhibitor Treatment Revenue Market Share in United States (2012-2017)
Table Pharming Group N.V. Basic Information List
Table Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Sales Growth Rate (2012-2017)
Figure Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Sales Market Share in United States (2012-2017)
Figure Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Plasma Protease C1-inhibitor Treatment
Figure Manufacturing Process Analysis of Plasma Protease C1-inhibitor Treatment
Figure Plasma Protease C1-inhibitor Treatment Industrial Chain Analysis
Table Raw Materials Sources of Plasma Protease C1-inhibitor Treatment Major Players/Suppliers in 2016
Table Major Buyers of Plasma Protease C1-inhibitor Treatment
Table Distributors/Traders List
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Type in 2022
Table United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Application in 2022
Table United States Plasma Protease C1-inhibitor Treatment Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Plasma Protease C1-inhibitor Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Plasma Protease C1-inhibitor Treatment Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources